Sanofi reported positive Sarclisa data from a registrational test in certain newly-diagnosed multiple myeloma patients, with the company anticipating a US launch as early as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.